About
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The company's pipeline currently consists of BL-8040, a platform for multiple cancer and hematological indications; and AGI-134, a synthetic immunotherapy in development for solid tumors.
The BioLineRx pipeline is generated by systematically identifying, validating, and in-licensing therapeutic candidates with advantages over current therapies or that address unmet medical needs.
BioLineRx also works with Novartis on the codevelopment of selected Israel-sourced novel drug candidates and has recently signed a collaboration agreement with MSD (known as Merck in the United States and Canada) to run a phase-2a study in pancreatic cancer using a combination of BL-8040 and Merck's Keytruda.
BioLineRx has received the FDA biological product designation for its novel cancer immunotherapy candidate AGI-134. In January 2020, the company announced that the European Commission had granted orphan drug designation to its lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer.
Funding history · 12 rounds · $208.6M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did BioLineRx become a publicly traded company on NASDAQ?
- BioLineRx became public on NASDAQ in March 2014, with an initial valuation of $10 million.
- What significant regulatory approval did BioLineRx receive in September 2023?
- In September 2023, BioLineRx announced FDA approval of APHEXDA™ (motixafortide) in combination with Filgrastim (G-CSF) for mobilizing hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.
- Which company did BioLineRx acquire in March 2017 and for what amount?
- In March 2017, BioLineRx acquired UK company Agalimmune for $6 million.
- What was a key development for BioLineRx's Motixafortide (BL-8040) in January 2020?
- In January 2020, the European Commission granted orphan drug designation to BioLineRx's lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer.
- What collaboration did BioLineRx establish with MSD (Merck) for pancreatic cancer?
- BioLineRx signed a collaboration agreement with MSD (Merck in the US and Canada) to conduct a Phase 2a study in pancreatic cancer, combining BL-8040 with Merck's Keytruda.
- When did BioLineRx announce the first patient dosed in a Phase 1 clinical trial for Motixafortide in sickle cell disease?
- In December 2023, BioLineRx announced the first patient was dosed in a Phase 1 clinical trial evaluating Motixafortide for CD34+ hematopoietic stem cell mobilization for gene therapies in sickle cell disease.
- What was the outcome of the Phase 1/2a study of AGI-134 in metastatic solid tumors, announced in December 2022?
- In December 2022, BioLineRx announced results from the Phase 1/2a study of its investigational anti-tumor vaccine AGI-134 in metastatic solid tumors.
- What was the most recent funding round for BioLineRx, and what was the amount?
- BioLineRx's most recent funding round was a PIPE in January 2025, raising $10 million.
- What is the current employee count for BioLineRx?
- BioLineRx currently has 54 employees.